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Abstract
Fibrosis is the end result of a complex series of events that follow tissue injury and inflammation. Pathophysiologic
fibrosis results in permanent scar formation, and can impair organ function. Fibrocytes are circulating, bone-
marrow-derived progenitor cells that traffic from the bone marrow to the injured organ via the bloodstream,
where they differentiate into fibroblasts and myofibroblasts, and play a pivotal role in both physiologic and
aberrant fibrosis. In this review, we focus on the contribution of fibrocytes to fibrotic diseases of the lungs and the
heart, including interstitial lung diseases, asthma, pulmonary hypertension, atherosclerosis and ischemic
cardiomyopathy.
Introduction
Fibrosis is the end result of a complex series of events
that follow tissue injury and inflammation. If this pro-
cess is faulty, excessive matrix deposition occurs and
normal tissue is replaced with permanent scar, resulting
in organ dysfunction. Fibrocytes are circulating bone-
marrow-derived progenitor cells that were first identified
in the context of an experimental model of wound
repair [1], and have since been shown to play a pivotal
role in both normal and aberrant healing in humans [2].
The striking similarities seen in fibroproliferative pro-
cesses involving both the lungs and the heart has
brought about the possibility of a common etiologic
mechanism [3]. In this review, we focus on a unique
mesenchymal progenitor cell, the fibrocyte, as the
potential common denominator in fibrotic diseases
affecting the lungs and the heart.
The fibrocyte
Fibrocytes were originally described when investigators
noted the early appearance of spindle-shaped cells that
expressed collagen, procollagen and CD34 in an experi-
mental skin wound repair model [1]. Their appearance
in the wound chamber, within 1 day after injury, was
much earlier than would be expected by entry of fibro-
blasts from the surrounding skin, and therefore these
cells were thought to originate from the circulation.
Thus, the investigators coined the word ‘fibrocyte’,a
combination of ‘fibroblast’ and ‘leukocyte’.I nh e a l t h y
humans, fibrocytes comprise 0.1-1.0% of nucleated cells
in peripheral blood, and have been found in a variety of
tissues in both healthy and diseased states [4-6].
Fibrocytes perform diverse functions that are impor-
tant in normal tissue repair and fibrosis. In addition to
mediating fibrogenesis by secreting inflammatory cyto-
kines, chemokines and growth factors [4,7], fibrocytes
also constitutively produce extracellular matrix proteins
(collagen I, collagen III and vimentin) and secrete
matrix metalloproteinases [7]. In addition, they play a
role in the recruitment and activation of T cells as anti-
gen-presenting cells [8], serve as the contractile force of
wound closure via a-smooth muscle actin (SMA)
expression [4,9], and promote angiogenesis [10].
Bone marrow origin, differentiation and homing of
fibrocytes
Bone marrow origin
Current data support the hypothesis that fibrocytes are
derived from the bone marrow. Fibrocytes express the
hematopoietic stem cell antigen CD34, the common
leukocyte marker CD45, the major histocompatibility
complex II, the myeloid markers CD11b and CD13, and
several fibroblast markers including vimentin, collagen I,
collagen III and fibronectin [1,5,6]. Fibrocytes also
express several chemokine receptors and adhesion mole-
cules [4,6]. Only a subset of circulating fibrocytes
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CD45 on fibrocytes decreases when the cells are
cultured or after they enter tissue. Because there is no
single marker unique for the identification of fibrocytes,
t h ec o e x p r e s s i o no fc o l l a g e np r o d u c t i o na n dC D 3 4o r
CD45 has been commonly used.
However, the progressive loss of CD34 and the even-
tual loss of CD45 can lead to an underestimation of
fibrocyte numbers. To address this issue, investigators
studied a comprehensive panel of markers and discov-
ered that human fibrocytes, but not peripheral blood
mononuclear cells, tissue macrophages or fibroblasts,
express the unique combination of CD45RO, 25F9 and
S100A8/A9 but not PM-2K [11]. Their findings suggest
that discrimination between these cells is possible, and
may facilitate studying the role of fibrocytes in fibrotic
diseases [11].
Differentiation
In culture, fibrocytes express CD34, CD45, collagen I
and vimentin. After exposure to transforming growth
factor (TGF)-b or endothelin-1, fibrocytes differentiate
into myofibroblast-type cells with expression of a-SMA,
production of fibronectin and collagen, and loss of
expression of CD34 and CD45 [4-6,9,12]. Other factors
shown to either promote or inhibit fibrocyte differentia-
tion include serum amyloid P [13,14], cytokines
[9,15-17], peroxisome proliferator-activated receptor-g
agonists [15]; leukotrienes [18], immunoglobulin G [19],
and gadolinium-containing contrast agents [20].
The differentiation of fibrocytes into myofibroblasts
has been studied in a variety of models including a
wound repair model [21] and a lung fibrosis model [22].
These authors reported that bone-marrow transplanta-
tion from green fluorescent protein (GFP) transgenic
animals to wild-type animals resulted in the presence of
c e l l si nt h et a r g e to r g a nt h a tc o e x p r e s s e dG F Pa n d
a-SMA, suggesting that the myofibroblasts were derived
from bone marrow [21,22]. In addition to fibroblasts
and myofibroblasts, fibrocytes have also been shown to
differentiate into other mesenchymal cell types in vitro
and in vivo, including adipocytes, osteoblasts and chon-
drocytes [23,24].
Homing
Fibrocytes use different chemokine ligand - receptor
pairs for tissue homing. Human fibrocytes express the
chemokine receptors chemokine (C-C motif) receptor
(CCR)3, CCR5, CCR7 and chemokine (C-X-C motif)
receptor (CXCR)4, whereas mouse fibrocytes express
CXCR4, CCR7 and CCR2 [5,6,9,25]. The chemokine
receptor - ligand pair CXCR4 - CXCL12 has been
shown to play a particularly important role in the hom-
ing of fibrocytes [26]. The differential expression of
CXCL12 in tissue results in the gradient required for
the homing of CXCR4 + cells. Fibrocytes were found to
express CXCR4 and to migrate in response to CXCL12
in vitro and in vivo in a model of bleomycin-induced
pulmonary fibrosis [5,27]. In this mouse model, anti-
body-mediated neutralization of CXCL12 led to reduced
fibrocyte recruitment to the lung and decreased collagen
deposition [5]. The importance of CXCL12 has also
been shown in patients with interstitial lung disease
[28]; in this study, not only were the numbers of CD45
+ collagen I + CXCR4 + fibrocytes significantly higher
than in normal controls, but expression of CXCL12 was
markedly elevated in the lung and plasma of patients
with lung fibrosis [28]. Other investigators have similarly
reported significantly higher levels of CXCL12 in the
plasma and lungs of patients with idiopathic pulmonary
fibrosis compared with healthy controls [29].
Fibrotic diseases of the lungs
Fibrotic lung diseases are characterized by varying
degrees of inflammation and fibrosis of the lung
parenchyma [30], and present clinically as progressive
deterioration as the lung tissue is replaced with scar
tissue. Idiopathic pulmonary fibrosis is the most com-
mon of the fibrotic lung diseases. Aberrant vascular and
airway remodeling and fibrosis are also seen in asthma
and pulmonary hypertension. Several lines of evidence
support the concept of a causal link between the accu-
mulation of fibrocytes at sites of lung tissue injury and
the development of lung fibrosis in these diseases.
Idiopathic pulmonary fibrosis
The important role that fibrocytes play in the develop-
ment of lung fibrosis has been reported by several
groups using different murine models of lung injury,
including those induced by irradiation [31], intrapul-
monary bleomycin [5,32] and intrapulmonary fluores-
cein isothiocyanate (FITC) [25]. In one report, female
C57BL/6 mice underwent total lung irradiation, and
were subsequently injected with cells from a clonal
GFP-positive male bone marrow stromal cell line or
male GFP-positive whole bone marrow, then assessed
for subsequent lung fibrosis and the contribution of the
Y-chromosome probe-positive GFP-positive cells to
areas of fibrosis [31]. Labeling of the fibrotic areas
revealed that cell division mainly occurred in the cells
positive for GFP Y-probe and vimentin, and that these
cells were macrophages and fibroblasts, suggesting bone
marrow origin [31]. In another study using a bleomycin-
induced lung fibrosis model, mice engrafted with bone
marrow from transgenic mice expressing GFP had
increased numbers of GFP-positive cells in areas of lung
fibrosis caused by the bleomycin compared with con-
trols, and flow cytometry of lung cells revealed a signifi-
cant increase in GFP-positive cells that were also
positive for collagen I [32]. Lastly, in another study,
investigators treated mice with severe combined
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and subsequently administered human fibrocytes to the
mice intravenously. Fibrocytes were shown to preferen-
tially home to the lungs of the mice that were pretreated
with bleomycin. In addition, in the immunocompetent
mice treated with bleomycin, the magnitude of lung
pro-collagen I and III upregulation correlated with the
number of fibrocytes in the bone marrow, blood and
lung [5]. In this study, levels of CXCL12 were higher in
the lungs of the mice treated with bleomycin, and
administration of neutralizing anti-CXCL12 antibodies
to bleomycin-treated animals led to a reduction in the
number of lung fibrocytes and myofibroblasts and
reduced lung collagen deposition, while other leukocyte
populations in the lung, were not affected [5].
Investigators using the FITC model of lung injury
showed that in CCR2-deficient mice challenged with
intrapulmonary FITC, fibrocyte recruitment to the lungs
was reduced, and wild-type mice that received CCR2
-/-
bone marrow had similarly reduced fibrocyte recruit-
ment to the lung and lower leve l so ff i b r o s i s[ 2 5 ] .T h i s
protective effect was reversed when bone marrow cells
from wild-type mice were transplanted into irradiated
CCR2
-/- mice. The same investigators also showed that,
unlike CCR2
-/- mice, CCL2
-/- mice are not protected
from FITC-induced lung fibrosis, as they are still able to
recruit fibrocytes to injured lung tissue, suggesting that
CCR2 ligands may play a role in human disease because
the recruitment of human fibrocyte precursors (CD14 +
CD16- monocytes) into inflamed tissue is dependent on
CCR2 [33].
Several groups have reported data regarding the role
of fibrocytes in fibrotic interstitial lung disease in
humans [28,29]. In one study, investigators compared
human lung tissue and peripheral blood from patients
with interstitial lung disease with that from normal con-
trols for the presence and number of fibrocytes and
their expression of the CXCL12 receptor [28]. Com-
pared with controls, patients with interstitial lung dis-
ease had extensive expression of CXCL12 in lung and
plasma. Moreover, patients with interstitial lung disease
had a number of circulating fibrocytes (collagen-I
expressing CD45 + cells) that was an order of magni-
tude higher than that in normal controls [28]. In a sub-
sequent study, other investigators quantified fibrocytes
in the lung tissue, plasma and bronchoalveolar lavage in
patients with idiopathic pulmonary fibrosis [29]. They
found a positive correlation between the number of lung
fibrocytes and the extent of lung fibrosis (r =0 . 7 9 ;P <
0.02) and found no fibrocytes in normal lungs. CXCL12
was detectable in the bronchoalveolar fluid in 40% of
patients with interstitial lung disease, whereas none was
detected in normal controls. Moreover, the concentra-
tion of CXCL12 in the plasma of patients with
idiopathic pulmonary fibrosis was significantly higher
than in healthy controls [29], suggesting that circulating
fibrocytes are recruited through the CXCR4 - CXCL12
axis and contribute to lung fibrosis in this patient popu-
lation. More recently, fibrocytes have been shown to be
an indicator of disease activity in patients with
idiopathic pulmonary fibrosis [34]. These investigators
compared fibrocyte levels in peripheral blood samples in
patients with idiopathic pulmonary fibrosis (stable and
during an exacerbation), patients with acute respiratory
distress syndrome, and normal controls. Fibrocytes were
significantly elevated in patients with stable idiopathic
pulmonary fibrosis compared with normal controls, and
were significantly increased during acute exacerbations
of the disease. The number of fibrocytes in patients with
acute respiratory distress syndrome was not significantly
different from patients with stable idiopathic pulmonary
fibrosis or normal controls [34]. Lastly, the mean survi-
val of patients with fibrocyte levels of >5% of total blood
leukocytes was 7.5 months compared with 27 months in
those with < 5% (P < 0.0001).
The concept of fibrocyte CXCR4 regulation as a thera-
peutic target in pulmonary fibrosis has been recently
reported by several groups using the bleomycin-induced
model of lung fibrosis [22,35]. One group showed that
in this model, fibrocytes homed from the bone marrow
to the lungs, and treatment with the mammalian target
of rapamycin (mTOR) inhibitor sirolimus attenuated the
numbers of fibrocytes in the blood and lungs, and was
associated with decreased collagen deposition in the
lungs. They also found that CXCR4 was the major che-
mokine receptor on fibrocytes, and that its expression
was induced by hypoxia and via the phosphoinositide 3-
kinase (PI3K)/Akt/mTOR pathway [22]. Another group
of investigators showed that treatment of mice with
AMD3100, a CXCR4 antagonist, resulted in decreased
levels of CXCL12 in the bronchoalveolar fluid and
decreased numbers of fibrocytes in the lungs [35]. Col-
lagen deposition and pulmonary fibrosis were also atte-
nuated by treatment with AMD3100. Whether
pharmacologic inhibition of the CXCR4/CXCL12 axis
could modify the lung fibrotic process in humans has
yet to be determined, and is an area of active research.
Asthma
Recurrent airway inflammation and aberrant remodeling
is thought to be the basis of the fibrotic response seen
in patients with severe asthma. In one study, fibrocytes
were identified in the airways of patients with asthma,
and increased in number after antigen challenge [12].
There were increased numbers of CD34 + Col I + cells
and few CD34 + a-SMA + cells below the basement
membrane in the bronchial mucosa of patients with
asthma, and these cells increased significantly within
24 hours after exposure to allergen. In addition,
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Col I + cells constitutively expressed a-SMA, and addi-
tion of endothelin-1 and TGF-b1 resulted in an increase
in fibronectin and collagen III in the culture medium
[12]. Others have shown that in bronchial biopsies from
patients with mild asthma, cells expressing CD34, CD45
and a-SMA, consistent with fibrocytes, differentiated
into myofibroblasts and resulted in increased thickness
of the lamina reticularis [36]. Additional evidence that
these cells may be of fibrocytic origin comes from a
study that showed that CCR7 is expressed in the myofi-
broblasts in the bronchial mucosa of patients with
asthma [37]. Moreover, after observing increased pro-
duction of CCL19 and its receptor CCR7, these investi-
gators suggested that the CCL19 - CCR7 axis may play
a role in the recruitment of fibrocytes to the lungs in
patients with asthma [37]. Fibrocytes were also shown
to be increased in patients with asthma who have
chronic airway obstruction; in this study, the percentage
of bone marrow-derived fibrocytes in the peripheral
blood was higher in patients with chronic obstructive
asthma than in patients with asthma without chronic
airway obstruction or normal controls [38]. The investi-
gators also showed that the yearly decline in lung func-
tion was significantly associated with the percentage of
circulating fibrocytes in patients with chronic obstruc-
tive asthma. Recently, investigators have reported that in
patients with severe refractory asthma, the number of
fibrocytes was significantly increased in the lamina pro-
pria compared with normal controls, and was also
increased in the peripheral blood [39].
Pulmonary hypertension
Pulmonary vascular remodeling is associated with fibro-
proliferative changes in the media and adventitia, and
with increased extracellular matrix deposition. Although
resident fibroblasts have been considered the primary
contributor to this process, more recently, the impor-
tance of bone marrow-derived fibrocytes in this process
has become apparent. In one study, the bone marrow of
GFP transgenic mice was transplanted into lethally irra-
diated syngeneic mice [40]. After 8 weeks, the chimera
mice were exposed to chronic hypoxia. Compared with
controls, marked vascular remodeling including medial
hypertrophy and adventitial thickening was observed in
the pulmonary arteries of the mice, and an abundance
of GFP-positive cells were observed in the pulmonary
arterial wall of the mice with hypoxia-induced pulmon-
ary hypertension. Most of these GFP-positive cells also
expressed a-SMA, indicating a myofibroblast phenotype.
The investigators concluded that bone-marrow-derived
cells mobilized to the hypertensive pulmonary arteries
and contributed to the pulmonary vascular remodeling.
Others have also shown that circulating mesenchy-
mal progenitor cells contribute to hypoxia-induced
pulmonary vascular remodeling in animal models [41].
The contribution of circulating fibrocytes was confirmed
using depletion studies, and showed that a reduction in
fibrocytes in the circulation of chronically hypoxic rats
resulted in a marked attenuation of adventitial thicken-
ing and fibrosis.
Fibrotic diseases of the heart
Fibrosis has been shown to be an important factor asso-
ciated with the adverse ventricular remodeling seen in
ischemic cardiomyopathy [42-44], intimal hyperplasia
after revascularization [45], and atherosclerosis [46,47].
Fibrosis also appears to be important in the pathophy-
siology of myxomatous valve disease [48,49] and trans-
plant vasculopathy [50].
Myxomatous valve disease
The data supporting the role of fibrocytes in myxoma-
tous valve disease come mainly from two studies. In the
first study, investigators used immunohistochemical ana-
lysis to compare 14 mitral valves removed for myxoma-
tous degeneration with 11 normal mitral valves removed
at autopsy, and found that myxomatous valves contained
both vimentin and a-SMA, and had features of activated
myofibroblasts [49]. In the second study, investigators
compared the stromal cells within myxomatous mitral
valves and those within normal valves, and found that
the stromal cells in myxomatous valves were not only
increased in number, but also appeared hyperplastic,
were CD34 +, and had multipolar cytoplasmic processes
consistent with fibrocytes [48].
Intimal hyperplasia
Intimal hyperplasia, a common response of blood vessels
to mechanical injury, results in the thickening of the
tunica intima. It has been shown to be an important
cause of saphenous vein graft disease after bypass sur-
gery, and of recurrent stenoses after percutaneous revas-
cularization of coronary and peripheral arteries. In an in
vivo ovine model of carotid artery synthetic patch graft,
circulating leukocytes were shown to produce collagen
and a-SMA, and these cells were subsequently found by
immunohistochemistry to express a set of markers
unique to fibrocytes, namely, CD34, CD45, vimentin
and a-SMA [45]. These same investigators took mono-
cytes from human volunteers and cultured them; the
cultured cells expressed markers consistent with fibro-
cytes (CD34 + CD45 + Col I + a-SMA +) and were
morphometrically similar to the vascular smooth muscle
cells found in intimal hyperplasia [45], suggesting an
association between intimal hyperplasia and fibrocyte
migration.
Atherosclerosis
In a rabbit model of atherosclerosis, CD34 + progenitor
cells were identified within and overlying atherosclerotic
plaques in rabbits fed a high cholesterol diet compared
Keeley et al. Fibrogenesis & Tissue Repair 2011, 4:2
http://www.fibrogenesis.com/content/4/1/2
Page 4 of 6with controls. These cells stained positive for CD45,
RAM-11, prolyl-4 hydroxylase and a-SMA, suggesting a
hematopoietic origin and a fibroblast/myofibroblast phe-
notype [47]. Other investigators evaluating human caro-
tid endarterectomy specimens found evidence of
fibrocytes on immunohistochemistry staining, and sug-
gested that fibrocytes contribute to the formation and
stability of the fibrous cap [46]. Specifically, fibrocytes
were found in areas of plaque growth and healing. The
authors further characterized them to be spindle-shaped,
collagen-producing and colocalizing with TGF-b (which,
as noted before, is known to promote fibrocyte forma-
tion) [46].
Ischemic cardiomyopathy
Deposition and remodeling of connective tissue plays an
important role in cardiac repair after injury, and it is gen-
erally considered that both reactive and reparative fibrosis
contributes to the adverse remodeling seen in ischemic
cardiomyopathy [44]. Several investigators have evaluated
the potential role of fibrocytes in this process. In a closed
chest mouse model of ischemia - reperfusion cardiomyo-
pathy, increased numbers of small spindle-shaped cells
were noted in the myocardium, and these cells expressed
collagen I, a-SMA, CD34 and CD45 [44]. Moreover, after
administration of serum amyloid P, the number of these
myocardial spindle-shaped cells was decreased, and the
ischemia - reperfusion-induced fibrosis and subsequent
ventricular dysfunction were prevented [44]. In a separate
study, investigators determined whether bone-marrow-
derived cells contributed to cardiac fibrosis in the chroni-
cally failing heart, and whether certain chemokines played
a role [43]. In another study, investigators used the mam-
malian sterile 20-like kinase (Mst) 1 transgenic mouse, in
which overexpression of Mst1 results in caspase activa-
tion, increased apoptosis and dilated cardiomyopathy. In
this model, bone-marrow-derived cells were recruited in
significantly greater numbers in Mst1 versus control
mice. In addition, the investigators found that myocytes
constitutively secreted CXCL12, which was shown to
increase cardiac fibroblast migration by 59%, suggesting
that the recruitment of bone-marrow-derived cells plays
an important role in the pathogenesis of cardiac fibrosis
in heart failure, and that CXCL12 is involved in this
recruitment [43]. Lastly, while studying the role of
CXCL10 in cardiac repair after myocardial infarction,
investigators found that both CXCL10-null and wild-type
mice had comparable infarct size, but the CXCL10-null
mice exhibited a hypercellular early reparative response,
delayed contraction of scar, early dilation, and wall thin-
ning [42]. Interestingly, the absence of CXCL10 was asso-
ciated with intense infiltration with CD45 + a-SMA +
cells and with reduced recruitment of cells that expressed
CXCR3, the receptor for CXCL10. These findings suggest
that although CXCL10 may be important in infarct
healing, wound contraction and favorable remodeling, its
effects may be primarily due its direct effects on fibro-
blast migration and function [42].
Conclusion
The fibrocyte is a unique mesenchymal progenitor cell
found to be an important source of fibroblasts and myo-
fibroblasts during tissue repair and remodeling. In some
disease states, elevated circulating levels of fibrocytes are
associated with increased fibrosis and adverse clinical
outcomes. Gaining a better understanding of this impor-
tant cell has the potential to allow development of ther-
apeutic strategies to attenuate its negative effects in
fibrotic diseases.
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